Fresenius stock slips 0.70% to EUR 51.42 before Xetra
Published on 11/20/2026 at 08:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCredit Outlook Turns Positive
- Moody's changed Fresenius' credit outlook to positive from stable while affirming its Baa3 rating.
- Fresenius reported net leverage of 2.5 times and targets a range of 2.5 to 3.0 times net debt to EBITDA.
- The group is directing financial flexibility toward Medtech, Nutrition and Biopharma investments.
Fresenius stock was under pressure before the Xetra session after the healthcare group received a positive credit signal from Moody's. The rating agency changed its outlook to positive from stable and affirmed Fresenius' Baa3 rating.
Fresenius stock traded at EUR 51.42 on Lang & Schwarz at 08:02 CET on Friday, November 20, 2026, 0.70 percent below the Xetra close of Thursday, November 19. The move keeps the shares below the previous session's closing level as investors assess the latest credit assessment.
According to Fresenius, Moody's cited stronger growth, profitability, credit metrics and liquidity. Chief Financial Officer Sara Hennicken said Fresenius had reduced its net leverage ratio to 2.5 times while continuing to invest in growth.
Investment Flexibility Remains In Focus
The group targets net debt of 2.5 to 3.0 times EBITDA and says its financial flexibility supports investments in Medtech, Nutrition and Biopharma. Fresenius also points to the acquisition of the remaining 45 percent stake in mAbxience and a development agreement with WuXi Biologics to expand its biosimilars pipeline.
Fresenius operates through Fresenius Kabi and Fresenius Helios and holds an approximately 20 percent investment in separately listed Fresenius Medical Care. Moody's is the third leading rating agency to move its Fresenius outlook to positive this year, according to the company.
The DAX provides the broader market setting for the German healthcare group.
More news and analyses on Fresenius stock.
